BioSpace News Archive

Viridian Therapeutics, Inc. today announced it will report its financial results from the first quarter ended March 31, 2022, after the financial markets close on Thursday, May 12, 2022.

Mustang Bio, Inc. today announced that interim Phase 1/2 data on treatment with the same lentiviral vector used in MB-107.

Codex DNA, Inc. today announced that it will release its first quarter 2022 financial results on Tuesday, May 10, 2022, after the market closes.

SeaStar Medical and LMF Acquisition Opportunities, Inc. today announced that SeaStar Medical’s Selective Cytopheretic Device (SCD) has received a Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today reported first quarter 2022 financial results and provided a corporate update.

Aligos Therapeutics, Inc. today announced that the company will present three posters highlighting data from three of the company’s programs in chronic hepatitis B (CHB) at the European Association for the Study of the Liver’s International Liver Congress 2022.

Pliant Therapeutics (NASDAQ: PLRX) announced today that PLN-74809 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the potential treatment of idiopathic pulmonary fibrosis (IPF).

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the start of a preclinical collaboration on Kabuki Syndrome with researchers from Kennedy Krieger Institute and Johns Hopkins University.

IVERIC Bio, Inc. reported that on May 2, 2022, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to six newly-hired, non-executive employees.

Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy.